Tiziana Life Sciences Ltd.: Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn's Disease
- Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b Clinical Study NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq:
Kunwar Shailubhai Irina Koffler Hana Malik Tiziana Life Sciences Tiziana Life Sciences Ltd Tiziana Life Sciences Ltd Nasdaq
Source: finanznachrichten.de